Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07444684
PHASE2
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
View on ClinicalTrials.gov
Summary
This study aims to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 Injection in patients with pyoderma gangrenosum.
Official title: A Phase II Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 Injection in Adult Patients With Pyoderma Gangrenosum
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-03-05
Completion Date
2028-04
Last Updated
2026-03-03
Healthy Volunteers
No
Conditions
Interventions
DRUG
SHR-1139 Injection
SHR-1139 injection.
Locations (1)
Shandong First Medical University Affiliated Dermatology Hospital
Jinan, Shandong, China